Skip to main
MXCT
MXCT logo

MaxCyte (MXCT) Stock Forecast & Price Target

MaxCyte (MXCT) Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

MaxCyte Inc. is positioned favorably in the growing Cell and Gene Therapy (CGT) industry, with ongoing innovations in non-viral delivery systems highlighting its relevance and potential within the sector. The company demonstrated resilience, as Cell Therapy revenue exceeded expectations by approximately $0.4 million, indicating robust demand for its proprietary Flow Electroporation platform. Furthermore, the maintained revenue guidance of $6 million underscores MaxCyte's stable financial outlook despite broader market competitiveness.

Bears say

MaxCyte Inc. has revised its revenue expectations, anticipating flat to only modest growth of 5% year-over-year for FY24, following a significant 32% decline in core revenue for FY23, with consumable sales down by 42%. The company reported a preliminary revenue miss for Q3 2023 and has lowered its overall revenue guidance for FY23 to $34 million, indicating persistent operational challenges amplified by macroeconomic pressures. Additionally, a reliance on capital-intensive cell and gene therapy (CGT) markets, along with a history of sustained financial losses, raises concerns about the company's short-term viability and long-term growth prospects.

MaxCyte (MXCT) has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of MaxCyte and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About MaxCyte (MXCT) Forecast

Analysts have given MaxCyte (MXCT) a Strong Buy based on their latest research and market trends.

According to 4 analysts, MaxCyte (MXCT) has a Strong Buy consensus rating as of Jun 16, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

MaxCyte (MXCT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.